- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01102010
Postoperative Blood Transfusion for Frail Elderly With Hip Fracture
July 16, 2015 updated by: University of Aarhus
Postoperative Blood Transfusion for Frail Elderly With Hip Fracture - a Clinical Randomized Controlled Trial
Elderly with hip fractures are often frail and discharged from hospital after few days of hospitalisation.
Hip fracture surgery is often associated with blood loss, where the patient is at risk of developing anaemia.
Low haemoglobin level reduces the body's oxygen transport which causes impaired functional ability and strain on vital organs.
Acute anaemia is worse tolerated in elderly, than in younger patients.
Therefore this study aims to investigate whether there are effects of an expanded indication for blood transfusion in the frail elderly.
Study Overview
Detailed Description
All elderly patients aged 65 and above who are hospitalised from nursing home or sheltered housing facilities to the Orthopaedic Surgery Ward at Aarhus University Hospital with hip fracture and treated operatively, are eligible for this study.
According to sample size calculations 284 patients are needed.
Informed consent or deputy informed consent, if the patient is cognitively impaired, is needed.
Inclusion is dependent on a haemoglobin measure between 6 and 7 mmol/l 6 days after surgery at the latest.
Randomization will be computerised.
Randomization will determine intervention with blood transfusion and the measurement of haemoglobin is blinded to the patient, relatives, and endpoint assessor.
Both transfusion groups will receive blood when haemoglobin is less than 6 mmol/l, as recommended by the Danish Health and Medicine Authority.
Geriatric and Orthopaedic Team (GO-team), consisting of following trained specialists: physiotherapist, nurse, and physician, will conduct medical evaluations, including blood transfusions, from admission until 30 days after surgery.
The GO-team will work on weekdays both at the Orthopaedic surgery ward and in the patients home immediately after discharge.
In accordance with Aarhus Blood Bank's instructions, blood transfusions are given both under hospitalisation, in the nursing homes and in the sheltered housings.
Outcomes are functional ability and mortality during 90 days, and overall quality of life (OQoL) after 30 days and 1 year.
The association between physical recovery and OQoL are tested.
Study Type
Interventional
Enrollment (Actual)
284
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Central Denmark Region
-
Aarhus, Central Denmark Region, Denmark, 8000
- Research Unit, Geriatric Department, Aarhus University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of hip fracture
- Surgery treatment
- Living in nursing homes or sheltered housing facilities
- Haemoglobin level between 6 and 7 mmol/l latest 6th day after surgery
- Written consent
Exclusion Criteria:
- Active cancer
- Pathological fracture
- The patient is against blood transfusion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Blood transfusion
Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl) Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl) |
An expanded indication for blood transfusion in the frail elderly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional ability
Time Frame: Measured 10 days after surgery + repeated measurement during 90 days after surgery
|
Measurement by Cumulated Ambulation Score (CAS), New Mobility Score (NMS) and Modified Barthel Index (MBI)
|
Measured 10 days after surgery + repeated measurement during 90 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: Measured 30 and 90 days after surgery
|
Measurement by the Danish Central Office of Civil Registration
|
Measured 30 and 90 days after surgery
|
|
Quality of Life
Time Frame: Measured 30 days and 1 year after surgery
|
Measurement by Depression List (DL)
|
Measured 30 days and 1 year after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delirium
Time Frame: Percentage of participants with delirium measured 10 days after surgery by the score 'Confusion Assessment Method'
|
It is an ancillary study to the trial to examine delirium as an outcome in a subsample of 179 nursing home residents.
Furthermore, we evaluate if delirium is associated with mortality.
|
Percentage of participants with delirium measured 10 days after surgery by the score 'Confusion Assessment Method'
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
October 1, 2013
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
April 8, 2010
First Submitted That Met QC Criteria
April 9, 2010
First Posted (Estimate)
April 12, 2010
Study Record Updates
Last Update Posted (Estimate)
July 20, 2015
Last Update Submitted That Met QC Criteria
July 16, 2015
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PBTFEHF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hip Fracture
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingHip Fractures | Pathological Fracture | Pathological Fracture of Hip | Hip Fracture PathologicUnited States
-
Sakarya UniversityNot yet recruitingHip Fracture SurgeriesTurkey
-
NYU Langone HealthRecruiting
-
University Health Network, TorontoRecruitingSurgery | Hip-fractureCanada
-
Lund UniversityMalmo Municipality, SwedenRecruiting
-
Hvidovre University HospitalCompleted
-
Michal Roll PhD,MBATel-Aviv Sourasky Medical CenterUnknown
-
JointResearchActive, not recruitingHip Fracture | Hip Fracture SurgeriesNetherlands
-
Guy's and St Thomas' NHS Foundation TrustCompletedHip Fractures | Fracture of Hip | Fractured HipUnited Kingdom
Clinical Trials on Blood transfusion
-
Hamad Medical CorporationSidra Medical and Research Center; World Anti-Doping Agency; Anti-Doping Lab... and other collaboratorsUnknownBlood Disease | Blood Transfusion, Autologous | Blood Doping | Blood Transfusion, HomologousQatar
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsCompletedThe Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy VolunteersFrance
-
Bristol-Myers SquibbCompletedLower-risk Myelodysplastic SyndromesJapan
-
Hospital PitangueirasUnknown
-
Emory UniversityWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Leukemia | Anemia | Myelodysplastic Syndrome | Aplastic Anemia | Bone Marrow FailureUnited States
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; University of Maryland; University of California, San... and other collaboratorsRecruitingThrombocytopenia | Severe MalariaUnited States, Zambia
-
Direction Centrale du Service de Santé des ArméesFloralis; TIMC-IMAGCompletedTrauma | Coagulopathy | Acute HemorrhageFrance
-
Weill Medical College of Cornell UniversityNational Institute of Neurological Disorders and Stroke (NINDS)SuspendedGlucose Transporter Type 1 Deficiency Syndrome | GLUT1DS1United States
-
Haukeland University HospitalDentsply Sirona Implants and ConsumablesCompleted
-
Mahidol UniversityWolf Schleinzer Stiftung zur Wissenschafts- und Bildungsförderung, GermanyCompletedSurgery | Immune Defect | Incompatible Blood TransfusionThailand